{"id":12907,"date":"2026-02-14T13:54:08","date_gmt":"2026-02-14T13:54:08","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/12907\/"},"modified":"2026-02-14T13:54:08","modified_gmt":"2026-02-14T13:54:08","slug":"got-500-2-pharma-stocks-to-buy-and-hold-forever","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/12907\/","title":{"rendered":"Got $500? 2 Pharma Stocks to Buy and Hold Forever."},"content":{"rendered":"

Key Points<\/p>\n

Stocks in the healthcare sector can often serve as a hedge against broader market volatility.<\/p>\n

But there are also some high-flying growth stocks, particularly within the pharmaceutical and biotech industries.<\/p>\n

These two pharma stocks play both roles and would be good long-term investments.<\/p>\n

Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well when the larger stock markets do not.<\/p>\n

But it depends on which industry. In the pharmaceutical<\/a> or biotech industries, for example, some stocks tend to behave more like growth stocks. A nice feature of investing in the sector is the ability to find high-flying growth stocks and balance them out with more stable defensive stocks.<\/p>\n

Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue \u00bb<\/a><\/p>\n

Even if you had just $500 to invest, I would probably look at one from each side and focus on those with plenty of long-term upside. Two good stocks to buy and hold for the long haul are Novo Nordisk(NYSE: NVO) and AbbVie(NYSE: ABBV).<\/p>\n

\"A<\/p>\n

Image source: Getty Images.<\/p>\n

1. Novo Nordisk<\/p>\n

Novo Nordisk<\/a> would be considered one of those high-growth-potential healthcare stocks. But what makes it even more attractive right now is its low valuation.<\/p>\n

Novo Nordisk is a global pharmaceutical company based in Denmark that is one of the leaders in making GLP-1 (glucose-like peptide 1) drugs, which are approved for weight loss and diabetes management. Along with Eli Lilly, Novo Nordisk is the dominant player in this space with its weight management drug Wegovy and its diabetes management drugs Ozempic and Rybelsus.<\/p>\n

In fiscal 2025, its diabetes and obesity care drugs saw sales increase 7%, with a 26% gain in obesity care drugs. For 2026, sales growth is targeted at 5% to 13% and will be positively impacted by a reversal of sales rebate provisions in the U.S.<\/p>\n

Experts predict that the GLP-1 market will grow to $254 billion by 2034, which would be a compound annual growth rate of 17%, so this market is not slowing down, and Novo Nordisk stands to reap the benefits for years.<\/p>\n

And, as mentioned, the stock is cheap right now, trading at 13 times earnings, so it looks like a no-brainer. You can buy Novo Nordisk stock for $49 per share, so with $500, you could buy 10 shares.<\/p>\n

2. AbbVie<\/p>\n

But if you wanted to balance that Novo Nordisk stock purchase out and use half of your available funds on a more defensive stock, consider AbbVie.<\/p>\n

AbbVie, which was spun off of Abbott Labs in 2013, has been a great defensive stock over the years, rising some 24% during the 2022 bear market when the S&P 500 dropped 18%. It is also a fantastic dividend stock<\/a>, increasing its dividend for the past 13 years since it split from Abbott. It currently has a high yield of 3.1%.<\/p>\n

In addition, AbbVie stock has been a strong performer, averaging a 20% total annual return over the past 10 years (with the dividend reinvested).<\/p>\n

The stock is also relatively cheap, trading at 15 times forward earnings, and it has significant growth potential with several blockbuster drugs. It seems to have made the transition from Humira, which is facing the patent cliff in 2028, to drugs like Skyrizi and Rinvoq, which saw net revenue gains of 33% and 30% in 2025, respectively.<\/p>\n

Analysts see the stock price rising 11% over the next 12 months to $250 per share. One share of AbbVie and five or six shares of Novo Nordisk could be a solid long-term investment for $500.<\/p>\n

Should you buy stock in Novo Nordisk right now?<\/p>\n

Before you buy stock in Novo Nordisk, consider this:<\/p>\n

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you\u2019d have $409,108!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,145,980!*<\/p>\n

Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 886% \u2014 a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n

See the 10 stocks \u00bb<\/a><\/p>\n

*Stock Advisor returns as of February 14, 2026. <\/p>\n

Dave Kovaleski<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"Key Points Stocks in the healthcare sector can often serve as a hedge against broader market volatility. But…\n","protected":false},"author":2,"featured_media":12908,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[438,1275,1414,4007,4002,4003,1963,4004,5889,272,4009,4008,4005,4006,4011],"class_list":{"0":"post-12907","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-business","9":"tag-business-news","10":"tag-economy","11":"tag-finance","12":"tag-financial-information","13":"tag-investing","14":"tag-investor","15":"tag-market-news","16":"tag-motley-fool","17":"tag-novo-nordisk","18":"tag-press-releases","19":"tag-sedar","20":"tag-stock-research","21":"tag-stock-valuation","22":"tag-the-globe-and-mail"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/12907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=12907"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/12907\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/12908"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=12907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=12907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=12907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}